PO.CH02.02 · 化学

9-channel spatial co-detection of clinically relevant protein and RNA targets in FFPE tumors with HCR™ Gold and MoxiePlex

编号 7673 展板 27 时间 4/22 09:00–12:00 区域 Section 38 主讲 Wudy Yang
分会场 Multi-Omics, Systems Biology, and Biological Mass Spectrometry
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Wudy Yang1, Randy Chen1, Harry Choi1, Aneesh Acharya1, Minakshi Singh2, Quyen Vu3

1Molecular Instruments, Inc., Los Angeles, CA,2Hamamatsu Photonics Europe GmbH, Herrsching am Ammersee, Germany,3Hamamatsu Corporation, Bridgewater, NJ

摘要 Abstract

Background: High-plex spatial profiling of protein & RNA in FFPE tumors is increasingly important for characterizing tumor-immune interactions, but existing methods often limit exploration to predefined antibody panels, harsh stripping/eluting steps, and iterative cycles that compromise sample and target integrity and make assay development and validation burdensome. HCR™ Gold IF, enabled by the HiFi Encoder, supports enzyme-free fluorescent detection using unmodified, user-supplied primary antibodies and operates on the same amplification platform as HCR™ Gold RNA-FISH. Combined with the Hamamatsu MoxiePlex multispectral tissue imaging platform, which enables whole-slide single-round imaging of 7-9-plex panels without the need for cyclic-staining, this workflow offers a practical route to flexible, 7-9-plex protein and RNA co-detection in FFPE specimens. Methods: FFPE human tumor sections were stained with HCR™ Gold IF using encoded, clinically validated primary antibodies alongside HCR™ HiFi Probes. Two parallel multiplex configurations were tested on the MoxiePlex:1. 7-plex panel: DAPI, 425, 488, 546, 594, 700, 7502. 9-plex panel: DAPI, 425, 488, 514, 546, 594, 633, 700, 750Panels incorporated antibodies specific to cancer-relevant proteins (e.g., pan-CK, Ki-67, PD-L1, CD8, CD68) & RNA targets representing tumor and immune biology (e.g., EPCAM, CXCL9, CD274). For each fluorophore-target combination, single-stain reference slides were generated to establish exposure settings, verify filter performance, and quantify spectral bleed-through to enable spectral unmxing. Multiplex slides were imaged in a single acquisition round, and data were evaluated for signal intensity, channel crosstalk, expected biological localization, and concordance with single-stain references. Spectral unmixing was carried out automatically for the whole- slide image, following acquisition, as part of the imaging process. Results: HCR™ Gold IF & HCR™ Gold RNA-FISH produced bright, robust signals with preserved tissue architecture. In whole- slide multiplex imaging, protein and RNA targets localized to expected tumor and stroma regions highlighting immune infliltration in the tumor microenvironment, the expression of which. closely matched single-stain reference patterns. The MoxiePlex platform delivered consistent, whole-slide imaging performance with reproducible acquisition settings appropriate for routine 7-9-plex scanning. Conclusions: HCR™ Gold IF & HCR™ Gold RNA-FISH can be combined in a single-round workflow on the MoxiePlex to achieve up to 9-plex imaging of clinically relevant protein and RNA targets in FFPE tissue. This approach avoids stripping or photobleaching, maintains compatibility with validated antibodies and standard filter sets, and provides a practical path for flexible, 7-9-plex spatial assays in translational and clinical research.
利益披露 Disclosure
W. Yang, None.. R. Chen, None.. H. Choi, None.. A. Acharya, None.. M. Singh, None.. Q. Vu, None.

在会议检索中打开